ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA's Complete Response LetterGlobeNewsWire • 02/20/24
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual MeetingGlobeNewsWire • 02/05/24
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 01/17/24
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/09/23
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisGlobeNewsWire • 11/09/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 11/09/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 11/07/23
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 10/22/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 10/16/23
ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)GlobeNewsWire • 10/06/23
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical ImmunologyGlobeNewsWire • 10/03/23
ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In BothSeeking Alpha • 09/22/23
ARS Pharmaceuticals stock falls toward record selloff after FDA issues surprise CRL, requesting additional studiesMarket Watch • 09/20/23
FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional StudyGlobeNewsWire • 09/20/23
ARS Reports Second Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/10/23
ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including AnaphylaxisGlobeNewsWire • 06/20/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYPRNewsWire • 05/30/23
ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal SprayZacks Investment Research • 05/15/23